We previously demonstrated that lipopolysaccharide (LPS) administered intraperitoneally (i.p.) to pregnant Wistar rat dams, at embryonic days 15 and 16 (E15/16), induced a decrease of baseline locomotor activity and diminished reactivity to amphetamine in adult female offspring. In the present study we aimed to assess the duration of LPS-induced maternal immune activation (MIA) and investigate possible changes in levels of main neurotransmitters in fetal brain during MIA. We hypothesized that the observed behavioral changes may be linked with MIA-induced disturbance of prenatal GABAergic system development, especially with α5 GABA A receptors (α5GABA A Rs), expression of which takes place between E14 and E17. Thereafter, we set to investigate if later potentiation of α5GABA A Rs in offspring's preadolescence (from postnatal day 22-28) could prevent the deficit in locomotor reactivity to amphetamine observed in adulthood, at postnatal day P60. The elevation of IL-6 in amniotic fluid 6 h after LPS treatment (100 μg/kg, i.p.) at E15 was concurrent with a significant increase of GABA and decrease of glutamate concentration in fetal brain. Moreover, repeated administration of MP-III-022, a selective positive allosteric modulator of α5GABA A Rs, at a dose (2 mg/kg daily, i.p.) derived from a separate pharmacokinetic study, prevented the LPS-induced decrease in locomotor reactivity to amphetamine (0.5 mg/ kg, i.p.) in adult females. These results were not mirrored in the parallel set of experiments with male offspring from LPS-treated rats. The results suggest that pharmacological potentiation of α5GABA A Rs activity in preadolescence may ameliorate at least some of adverse consequences of exposure to MIA in utero.
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Introduction
Maternal immune activation (MIA) is one of the most investigated prenatal influences with potentially harmful effects on brain development. Epidemiological studies have linked the emergence of schizophrenia and several other neurodevelopmental disorders with an increased incidence of MIA caused by bacterial or viral infections during pregnancy (Brown and Derkits, 2010) . MIA is suggested to lead to a disbalance between pro-and anti-inflammatory cytokines in the fetal brain, which may ultimately impact in utero neurodevelopment and result in sustained long-lasting alterations in postnatal brain (Meyer et al., 2009 (Meyer et al., , 2011 . Several animal models of prenatal exposure to MIA, designed to mimic behavioral symptoms and elucidate pathophysiological mechanisms underlying the disorders related to abnormal fetal brain development, differ with respect to the challenging agents and the time of exposure (Harvey and Boksa, 2012) .
Lipopolysaccharide (LPS), a cell wall component of gram negative bacteria, induces febrile response and cytokine release when administered intraperitoneally to pregnant rodents. Due to a significant variability in LPS exposure protocols, a diversity of findings was reported, describing acute changes in fetal compartment, as well as behavioral symptoms and morphological alterations in offspring. Nevertheless, the changes observed in a number of studies on LPS-treated rodents are consistent with those seen in schizophrenia patients, including
